American biotech firm Moderna is pursuing regulatory approval for its Covid-19 vaccine in children under six years of age after the two-shot regimen was found to be safe and produced a strong immune response, the company said on Mac 23 (2022).
Specifically, two doses of 25mcg given to babies, toddlers and preschoolers, generated similar levels of antibodies to two doses of 100mcg given to young people aged 18-25, indicating that there would be similar levels of protection.
Already a subscriber? Log in.
Get 30% off with our ads free Premium Plan!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!